The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 08, 2020
Filed:
Apr. 23, 2018
Applicants:
Viracta Therapeutics, Inc., San Diego, CA (US);
Trustees of Boston University, Boston, MA (US);
Inventors:
Ronald J. Berenson, Mercer Island, WA (US);
Douglas V. Faller, Weston, MA (US);
Assignees:
TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US);
VIRACTA THERAPEUTICS, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/52 (2006.01); A61K 31/522 (2006.01); A61K 31/167 (2006.01); A61K 31/19 (2006.01); A61K 31/27 (2006.01); A61K 31/4045 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01); A61K 38/12 (2006.01); A61K 31/18 (2006.01); A61K 9/00 (2006.01); A61K 31/165 (2006.01); A61K 31/473 (2006.01); A61K 31/4402 (2006.01); A61K 38/15 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 9/0053 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 31/19 (2013.01); A61K 31/27 (2013.01); A61K 31/4045 (2013.01); A61K 31/4402 (2013.01); A61K 31/473 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/522 (2013.01); A61K 38/12 (2013.01); A61K 38/15 (2013.01); A61K 45/06 (2013.01); Y02A 50/467 (2018.01);
Abstract
Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.